Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
:LTRN
Lp-284
Advanced Solid Tumor, Relapsed Or Refractory Lymphomas
Phase I
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Nov 03, 2023
―
Olaparib, Spironolactone, Lp-184
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Nsclc, Metastatic Solid Tumor, Tnbc - Triple-Negative Breast Cancer, Gbm, Ddr Gene Mutation
Phase I/II
Recruiting
Study of LP-184 in Patients With Advanced Solid Tumors
Jun 23, 2023
―
Pemetrexed, Carboplatin, Lp-300
Carcinoma, Non-small-cell Lung, Adenocarcinoma Of Lung
Phase II
Recruiting
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Jul 06, 2022
―
Irofulven, Prednisolone 10 Mg
Metastatic Castration-Resistant Prostate Cancer Patients
Phase II
Completed
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Aug 21, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lantern Pharma, Inc. (LTRN) have in its pipeline
LTRN is currently developing the following drugs: Lp-284, Olaparib, Spironolactone, Lp-184, Pemetrexed, Carboplatin, Lp-300. These drug candidates are in various stages of clinical development as the company works toward FDA approval.